Doxorubicin Cardiomyopathy

Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.

[1]  N. Bachur,et al.  NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Fischman,et al.  Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Sisson,et al.  Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R. Gottlieb,et al.  Chemotherapy and cardiotoxicity. , 2008, Reviews in cardiovascular medicine.

[5]  J. Karliner,et al.  Vincristine attenuates doxorubicin cardiotoxicity. , 2008, Biochemical and biophysical research communications.

[6]  K. Pritchard,et al.  Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. , 1997, Biochemistry.

[7]  I. Carrió,et al.  Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  R. Nagai,et al.  Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.

[9]  A. Benson,et al.  Biochemical determinants of Adriamycin toxicity in mouse liver, heart and intestine. , 1992, Biochemical pharmacology.

[10]  R. McKelvie,et al.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. , 2008, The Canadian journal of cardiology.

[11]  S. Matoba,et al.  Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. , 2003, Journal of the American College of Cardiology.

[12]  Yuichiro J Suzuki,et al.  Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. , 2003, Molecular pharmacology.

[13]  W. Haseltine,et al.  Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. , 1981, The Journal of biological chemistry.

[14]  D. Sawyer,et al.  Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. , 1999, Circulation research.

[15]  J. Joseph,et al.  Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide Synthase , 2001, The Journal of Biological Chemistry.

[16]  U. Völker,et al.  The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. , 2007, Cancer research.

[17]  A. Othman,et al.  Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats , 2001, Free radical research.

[18]  M. Aricò,et al.  Long term survival after heart transplantation for doxorubicin induced cardiomyopathy. , 1991, Archives of disease in childhood.

[19]  Y. Rojanasakul,et al.  Vanadate Induces p53 Transactivation through Hydrogen Peroxide and Causes Apoptosis* , 2000, The Journal of Biological Chemistry.

[20]  F. Marumo,et al.  Myocardial Uptake of 111In Monoclonal Antimyosin Fab in Detecting Doxorubicin Cardiotoxicity in Rats: Morphological and Hemodynamic Findings , 1992, Circulation.

[21]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[22]  M. Runge,et al.  Doxorubicin-Induced Cardiomyopathy , 2000 .

[23]  J. Doroshow,et al.  The effect of doxorubicin on hepatic and cardiac glutathione. , 1979, Research communications in chemical pathology and pharmacology.

[24]  J. Doroshow,et al.  Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. , 1986, The Journal of biological chemistry.

[25]  R. Weiss.  The anthracyclines: will we ever find a better doxorubicin? , 1992, Seminars in oncology.

[26]  D. Mochly‐Rosen,et al.  A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. , 1997, The Journal of biological chemistry.

[27]  A. Saraste,et al.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. , 2000, Cancer research.

[28]  E. Monti,et al.  Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. , 1995, Anticancer research.

[29]  G.,et al.  Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis , 2000 .

[30]  G. Takemura,et al.  Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. , 2007, Progress in cardiovascular diseases.

[31]  Lei Wang,et al.  Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. , 1998, Circulation research.

[32]  U. Simonis,et al.  Acute vincristine pretreatment protects adult mouse cardiac myocytes from oxidative stress. , 2007, Journal of molecular and cellular cardiology.

[33]  E. Arena,et al.  Repair kinetics of DNA, RNA and proteins in the tissues of mice treated with doxorubicin. , 1979, Arzneimittel-Forschung.

[34]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[35]  W. Roberts,et al.  Cardiac ultrastructural changes induced by daunorubicin therapy , 1973, Cancer.

[36]  J. Doroshow.  Effect of anthracycline antibiotics on oxygen radical formation in rat heart. , 1983, Cancer research.

[37]  P. Singal,et al.  Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. , 1985, The Canadian journal of cardiology.

[38]  P. Morandi,et al.  Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide , 2001, Bone Marrow Transplantation.

[39]  Kelvin,et al.  Redox Cycling of Anthracyclines by Cardiac Mitochondria , 2022 .

[40]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[41]  D. S. St. Clair,et al.  The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. , 2006, Cardiovascular research.

[42]  P. Singal,et al.  Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. , 2005, American journal of physiology. Heart and circulatory physiology.

[43]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[44]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[45]  R. Mason,et al.  Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. , 1980, Biochimica et biophysica acta.

[46]  S. Lipsitz,et al.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. , 2004, The New England journal of medicine.

[47]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[48]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[49]  D. Renlund,et al.  Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. , 1995, American heart journal.

[50]  R D Olson,et al.  Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. , 1980, The Journal of pharmacology and experimental therapeutics.

[51]  R. Kernoff,et al.  Acute and Chronic Cardiovascular Effects of Doxorubicin in the Dog: The Cardiovascular Pharmacology of Drug‐Induced Histamine Release , 1980, Journal of cardiovascular pharmacology.

[52]  E. Goetzl,et al.  The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. , 2001, Journal of molecular and cellular cardiology.

[53]  P. Singal,et al.  Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. , 1991, The American journal of physiology.

[54]  P. Singal,et al.  Subcellular effects of adriamycin in the heart: a concise review. , 1987, Journal of molecular and cellular cardiology.

[55]  R. Schwartz,et al.  Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Xianglin Shi,et al.  The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. , 2000, American journal of physiology. Cell physiology.

[57]  P. Singal,et al.  Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. , 1995, Journal of molecular and cellular cardiology.

[58]  ダニエル エル． フリン,et al.  Anti-cancer agents , 2003 .